Kiora Pharmaceuticals, Inc. (KPRX)

Latest News

View All News

October 29, 2026 7:00 AM EDT

Kiora Pharmaceuticals In-Licenses Late-Stage, Oral Neuroprotective Calpain Inhibitor for Central Retinal Artery Occlusion (CRAO) with Planned Expansion into NAION; Asset Completed Phase 3 Clinical Trial in CRAO in Japan

Sep 8, 2026 7:00 am EDT

Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs

Aug 19, 2026 7:00 am EDT

Kiora Pharmaceuticals Licenses South Korean Ophthalmic Development and Commercialization Rights for KIO-301 to Chong Kun Dang Pharmaceutical Corporation

Aug 7, 2026 7:00 am EDT

Kiora Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

View All News

Latest Presentation

Oct 29, 2026 Corporate & Pipeline Overview (Oct 2026)

View All Presentations

Company Overview

Kiora Pharmaceuticals (NASDAQ: KPRX) is a clinical-stage biopharmaceutical company developing advanced therapies for retinal disease. Our strategy is to target critical pathways underlying eye disease with innovative small molecules to preserve, slow down, or restore vision loss.

View Executive Team

Latest Financial Results

Q2 2026

Quarter Ended Jun 30, 2026

View All Financial Results

Earnings Release

10-Q XBRL Zip

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

View 10-K

IR Contacts

Headquarters

Kiora Pharmaceuticals, Inc.
169 Saxony Rd
Suite 212
Encinitas, CA 92024

Investor Relations

investors@kiorapharma.com

Corporate Presentation

Investor Relations

KIO-401 In-Licensing

Latest News

Latest Presentation

Company Overview

Latest Financial Results

Q2 2026

Latest Annual Filing

Stock Snapshot

IR Contacts

Headquarters

Investor Relations

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Corporate Presentation

Latest News

Email Alerts

Latest Presentation

Company Overview

Latest Financial Results

Q2 2026

Latest Annual Filing

Stock Snapshot

IR Contacts

Headquarters

Investor Relations